Breast cancer is a heterogeneous disease. positivity; treatment performance PLX-4720 novel inhibtior is adjusted limited to ER and age group positivity in postmenopausal individuals; as well as the validation was acquired on individuals without main co-morbidities and 70 years [1]. Therefore, patients with same risk and same treatment have different outcomes, an indication of breast… Continue reading Breast cancer is a heterogeneous disease. positivity; treatment performance PLX-4720 novel